
The first-quarter numbers for Emergent BioSolutions (NYSE:EBS) didn’t look too great. In fact, they were arguably ugly.

The first-quarter numbers for Emergent BioSolutions (NYSE:EBS) didn’t look too great. In fact, they were arguably ugly.

Rockville-based BeneVir Biopharm Inc., a biotech specializing in immunotherapy treatments for cancer, has reached a deal to sell to pharmaceutical goliath Janssen Biotech Inc., a Johnson & Johnson company, in a deal worth up to $1.04 billion.

Think of The Collective as a 15K SF clubhouse for big kids. Grownups are welcome, but leave your electronic devices in your pockets, please. This is about face-to-face fun.

1,129,744 patient records were breached between January and March 2018, according to new data released today in the Protenus Breach Barometer. Published by Protenus, an artificial intelligence platform used by top health systems to analyze every access to patient data inside the electronic health record (EHR), the Breach Barometer is the industry’s definitive source for health data breach reporting.

Landos Biopharma, Inc., an emerging biopharmaceutical company focused on developing improved treatments for autoimmune diseases, announced the publication of findings on the mechanisms of action for its top lead candidate, BT-11, in Inflammatory Bowel Diseases, the Official Journal of the Crohn’s & Colitis Foundation. The study concludes that through the activation of the Lanthionine Synthetase C-Like 2 (LANCL2) pathway, BT-11 induces changes in the interface of inflammation and metabolism within immune cells in the gut that are critical to provide lasting therapeutic efficacy against inflammatory bowel disease (IBD). These changes in metabolism enhance regulatory CD4+ T helper cell responses and promote lasting therapeutic actions locally within the gut. The mechanistic findings demonstrate the translatability of the therapeutic efficacy of BT-11 to the clinic.

When: Wednesday, May 16, 2018 from 5:00 PM to 7:00 PM EDT
Where: UMBC Shady Grove, 9630 Gudelsky Drive ,Rockville, MD 20850
Join BioBuzz and sponsor UMBC Shady Grove in Rockville on May 16th for our next great networking event. UMBC at The Universities at Shady Grove (USG) has a 17+ year history of providing high caliber and industry desired academic programs in Rockville, MD. This Fall, UMBC is launching its first Bachelors of Science degree at USG in Translational Life Science Technology. This degree, designed in partnership with Montgomery College, combines the theory of a traditional life science degree with real-world applications used by scientists in academic and industry research.

Provider venture funds are more active than ever before and their perspectives were a topic of discussion at the newest megaconference on the healthcare block — HLTH — which kicked off Sunday at the Aria hotel in Las Vegas.

This is the Letter of Intent Form (LOI) for Phase 0 of the VA BEACH BIO INNOVATION Startup Challenge. The Team Leader of each team should fill out and submit one form for this challenge. The last date to submit an LOI is May 31st.
Page 1: Basic information and Confidentiality Page 2: Additional Team information (can be completed during Phase 1)
Anyone can Enter!
No minimum team size – you can enter individually Your Background: Anyone with an entrepreneurial spirit! No Geography Restrictions: This challenge welcomes international participants

It was quite fascinating to cover the speech that Health and Human Services Secretary Alex Azar gave this week in Washington, D.C. In a keynote address on Wednesday morning at the Marriott Wardman Park Hotel, Secretary Azar laid out his agency’s overall policy strategy, for attendees at the World Health Care Congress, which annually gathers together leaders from all the major sectors of the U.S. healthcare industry, from hospitals to physician groups to post-acute and behavioral healthcare, to health plans/health insurers, employer-purchasers, pharmaceutical leaders, and healthcare IT leaders. It’s an ideal venue for senior federal healthcare officials to make announcements—and they usually do show up every year, and sometimes, make news.